APVO:NSD-Aptevo Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.80

Change

0.00 (0.00)%

Market Cap

USD 0.03B

Volume

0.04M

Average Target Price

USD 18.50 (+137.18%)
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD72.87B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

N/A

USD59.07B 21.90 16.92
SGEN Seattle Genetics, Inc

N/A

USD31.48B N/A N/A
MRNA Moderna, Inc

N/A

USD27.57B N/A N/A
RPRX Royalty Pharma plc

N/A

USD25.49B 35.14 9.58
GMAB Genmab A/S

N/A

USD25.19B 27.12 3.06
ALXN Alexion Pharmaceuticals, Inc

N/A

USD24.92B 30.43 27.52
BGNE BeiGene, Ltd

N/A

USD23.57B N/A N/A
IMMU Immunomedics, Inc

N/A

USD19.77B N/A N/A
INCY Incyte Corporation

N/A

USD18.98B 47.64 35.20

ETFs Containing APVO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1,090.84% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,090.84% 99% A+ 99% A+
Trailing 12 Months  
Capital Gain 1,030.43% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,030.43% 98% A+ 99% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 91.51% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 91.51% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 265.20% N/A N/A N/A N/A
Risk Adjusted Return 34.51% N/A N/A N/A N/A
Market Capitalization 0.03B 8% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.80 23% F 25% F
Price/Book Ratio 2.90 65% D 42% F
Price / Cash Flow Ratio -0.59 12% F 60% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -223.37% 13% F 5% F
Return on Invested Capital -104.67% 25% F 9% F
Return on Assets -52.37% 14% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.82 77% C+ 78% C+
Short Percent 2.30% 77% C+ 59% F
Beta 2.56 9% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector